Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Addyi Regrets? Not From FDA, Likely So For Valeant

This article was originally published in Scrip

Executive Summary

In a somewhat rare move, FDA officials took to the New England Journal of Medicine this week to give their perspective about why the agency this past August finally gave in and approved Sprout Pharmaceuticals Inc.'s controversial female libido-boosting pill Addyi (flibanserin) – describing the evaluation of the product as "challenging."

Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register